Zydus Lifesciences Limited — Investor Meet, 20-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Zydus Lifesciences reported Q1 FY26 consolidated revenues of ₹6570 Cr (up 6% YoY) and net profit of ₹1470 Cr (up 3% YoY), with a strong EBITDA margin of 31.8%. Net cash increased to ₹5630 Cr. The US business grew 3%, India branded formulations by 9%, and International markets by a robust 37%. Management anticipates single-digit US growth for FY26 with over 30 product launches. Strategic initiatives include scaling up 505(b)(2) products, expanding MedTech, and developing biologics CDMO capabilities. The company maintains a positive outlook on achieving its FY26 targets.